NSE · GRANULES
Granules India Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹948 Cr with net profit ₹109 Cr — a 11.45% net margin, versus 8.95% the period before.
Shareholding
As of 2026-09-30
- Promoter37.39%
- Public27.04%
- FII20.25%
- DII15.33%
1,82,022 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.74× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #19 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Granules India Limited(this company) | ₹21,813 Cr | 31.1 | 3.32 | 10.87% | 12.22% |
AI analysis
AI-generated · google/gemini-2.5-flashGranules India Limited is listed on the Indian markets with a market capitalization of Rs 21709 Cr. The company reported revenue of Rs 4494.53 Cr. The company's EPS stands at 24.41. The stock's 52-week high is Rs 910 and its 52-week low is Rs 432.6.
Positives
- +The company's debt-to-equity ratio is 0.34, indicating a reasonable level of debt.
- +The dividend yield is 20%, suggesting a significant return to shareholders.
- +Promoter pledge is 0% as of Jun 30, 2026, indicating no pledged shares by promoters.
Negatives
- −Revenue showed a negative growth of -0.5% for the reported period.
- −The latest available PE ratio is 106.45, which is relatively high.
- −Net profit declined from Rs 201.57 Cr in Mar 2026 to Rs 179.96 Cr in Jun 2026.
- −The number of shareholders increased from 103867 in Mar 2019 to 169422 in Jun 2026.
Financial performance
Granules India Limited reported an annual revenue of Rs 4494.53 Cr. The revenue growth rate was -0.5%. The company's profit margin was 11.15%. Quarterly revenue for Mar 2026 was Rs 1470.61 Cr, increasing slightly to Rs 1476.77 Cr in Jun 2026. Net profit for Mar 2026 stood at Rs 201.57 Cr, declining to Rs 179.96 Cr in Jun 2026.
Profitability & Returns
The company's Return on Equity (ROE) is 11.7% and Return on Capital Employed (ROCE) is 13.63%. The Earnings Per Share (EPS) is 24.41. The profit margin for the latest reported period was 11.15%. The PE ratio is 106.45.
Balance Sheet
The debt-to-equity ratio of Granules India Limited is 0.34. The book value per share is Rs 190.45. The company has a current market capitalization of Rs 21709 Cr.
Ownership & Pledges
As of June 30, 2026, promoter shareholding in Granules India Limited was 38.0165%. Public shareholders held 28.3751%, while FIIs held 17.4987% and DIIs held 16.1097%. There are no promoter shares pledged, as indicated by a promoter pledge of 0% for the period ending June 30, 2026.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.